Curated News
By: NewsRamp Editorial Staff
March 12, 2026
Oragenics Launches Phase IIa Trial for Concussion Treatment in Australia
TLDR
- Oragenics' Phase IIa trial milestone positions it as a leader in developing the first pharmacological treatment for concussion, offering investors early access to a potential breakthrough therapy.
- Oragenics initiated its Phase IIa trial for ONP-002 in Australia, enrolling 40 patients with acute concussion to evaluate safety and preliminary efficacy using intranasal delivery technology.
- This trial advances a potential treatment for 69 million annual concussion sufferers worldwide, offering hope for improved recovery and quality of life through accessible brain-targeted therapy.
- Oragenics bypasses the blood-brain barrier with intranasal delivery, administering ONP-002 within 12 hours of injury to directly target the brain in concussion patients.
Impact - Why it Matters
This development represents a potentially transformative advancement in treating traumatic brain injuries, which affect millions globally each year without current pharmacological solutions. Concussions and mild traumatic brain injuries have significant long-term consequences for cognitive function, mental health, and quality of life, particularly affecting athletes, military personnel, and accident victims. The rapid administration window (within 12 hours of injury) and direct brain delivery mechanism could fundamentally change emergency and post-injury care protocols. Successful development of ONP-002 would address a massive unmet medical need while validating intranasal delivery as a viable pathway for neurological treatments, potentially opening doors for other brain-targeted therapies. For investors, this milestone demonstrates tangible progress in Oragenics' clinical pipeline and execution capabilities.
Summary
Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company, has achieved a significant milestone by completing the first site initiation visit for its Phase IIa clinical trial of ONP-002 in Australia. This formal launch of clinical trial operations at the initial site marks a crucial step forward for the company's pioneering work in brain-targeted therapeutics using proprietary intranasal delivery technology. The randomized, placebo-controlled study will enroll 40 patients with acute concussion or mild traumatic brain injury, administering the first dose within 12 hours of injury to assess safety, tolerability, and preliminary clinical signals. With two additional sites completing Research Governance Office reviews following earlier Human Research Ethics Committee approval, all three locations are poised to begin patient enrollment and dosing imminently, accelerating the development timeline for this potentially groundbreaking treatment.
ONP-002 represents a first-in-class intranasal neurosteroid being developed for concussion and mild traumatic brain injury (mTBI), conditions that affect approximately 69 million people globally each year without any approved pharmacological treatment available. Oragenics' innovative intranasal delivery platform is designed to bypass the blood-brain barrier, enabling rapid, non-invasive delivery of therapeutics directly to the brain. The company is actively exploring opportunities to broaden its central nervous system pipeline through both internal development and strategic business development initiatives. For more detailed information about this clinical advancement, readers can view the full press release through the InvestorBrandNetwork.
InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, provides advanced wire-grade press release syndication services for companies like Oragenics, ensuring broad distribution through multiple channels including article syndication to over 5,000 outlets, enhanced press release optimization, and comprehensive social media distribution. This extensive network helps companies reach diverse target markets, demographics, and industries effectively, cutting through information overload to deliver unparalleled recognition and brand awareness for their clinical and corporate developments.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Launches Phase IIa Trial for Concussion Treatment in Australia
